Safety and Activity of Anti-CD14 Antibody IC14 (atibuclimab) in ALS: Experience with Expanded Access Protocol.
Dario GelevskiGrace AddyMargot RohrerCaroline CohenAimee RoderickAllison WinterJudith CareyJennifer ScaliaMegan YertonHarli WeberMichael DoyleNeil ParikhGeli KaneAmy EllrodtKatherine M BurkeDerek D'AgostinoErvin SinaniHong YuAlexander ShermanJan AgostiGarry RedlichPatrick CharmleyDavid CroweMark ApplebyBrian ZiegelaarKatherine HanusZhenhua LiSuma BabuKatharine NicholsonSarah LuppinoJames BerryClare Baecher-AllanSabrina PaganoniMerit E CudkowiczPublished in: Muscle & nerve (2022)
Administration of IC14 in ALS was safe and well-tolerated in this intermediate-size EAP. Measuring RO guided dosing frequency. Additional placebo-controlled trials are required to determine the efficacy of IC14 in ALS. This article is protected by copyright. All rights reserved.